News & Announcements
Campus Company LoQus23 Therapeutics Hoping to Slow the Progression of Huntington's Disease
14 October 2024
LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company investigating small molecule drugs that could stop DNA instability and slow neurodegeneration in Huntington’s Disease, myotonic dystrophy type 1 and similar triplet repeat expansion diseases, today announces the successful close of its £35 million (c.$43 million) Series A financing.
LinkGevity Awarded Highly Competitive Women TechEU Grant
14 October 2024
LinkGevity, an AI-driven drug discovery company focused on longevity and age-related disease, has been selected to receive a highly competitive Women TechEU grant. Women TechEU is a project funded through Horizon Europe, the EU’s flagship research and innovation funding program.
Fantastic News from Campus Companies RXCelerate & PlaqueTec
14 October 2024
Two of our companies on site have successfully completed a collaboration to assess small molecules identified from an initial cheminformatics drug screen in a bespoke cell-based assay developed by RxCelerate on one of PlaqueTec’s targets discovered in pilot studies.
RXCelerate Limited Delighted to rank 21st in the Top 200 Women Powered Businesses 2024 Report
14 October 2024
Huge congratulations to Campus company RXCelerate for featuring in the JPMorgan & Beauhurst 2024 Report for the top 200 women powered businesses.
ExpressionEdits News!
14 October 2024
Expression Edits have been named in Labiotech as one of 10 start-ups to watch in 2024.
bit.bio at the Neuroscience 2024 Annual Conference
14 October 2024
bit.bio, the company coding human cells for novel cures and a pioneer in the field of synthetic biology, announced its comprehensive program for Neuroscience 2024, the annual meeting of the Society for Neuroscience (SfN).
Cambridge joins forces with ARIA to fast-track radical new technologies to revolutionise brain health
09 October 2024
A large team from across the Cambridge life sciences, technology and business worlds has announced a multi-million-pound, three-year collaboration with the Advanced Research and Invention Agency (ARIA), the UK Government’s new research funding agency.
The Babraham Research Campus: Unlocking a solution to science space scarcity
26 September 2024
The timely availability of space at Babraham Research Campus presents an immediate opportunity for ambitious life science ventures, explore more here…
Accelerate@Babraham selects its next set of science superstars!
29 May 2024
Six life science start-ups looking to develop products and services to make a positive difference to healthcare have been selected.
Mission Therapeutics raises £25.2 million to progress clinical candidates in the area of mitophagy
25 March 2024
Mission Therapeutics announces it has raised £25.2 million to progress the clinical development of its drug candidates.
Biotech start-up BugBiome secures investment for pioneering research in sustainable pest protection
12 February 2024
BugBiome, a biotech harnessing nature’s microbial defences for pest protection to benefit human and planet health, has successfully closed a pre-seed funding round, securing £310k from Cambridge Angels and Discovery Park Ventures.
Maxion Therapeutics Welcomes Dr Arndt Schottelius as New CEO
02 February 2024
Maxion Therapeutics announced today that Dr Arndt Schottelius has been appointed as the new Chief Executive Officer, effective on 1 March 2024, to take the Company to its next phase of development.
PlaqueTec and the Babraham Institute collaborate on phenotypic screen of coronary artery blood
23 January 2024
PlaqueTec and the Babraham Institute today announced a collaboration to develop a cell phenotyping assay to detect cell subpopulations in human blood.
Welcoming Health Innovation East, the new name for Eastern AHSN
07 December 2023
Our partner, Eastern AHSN has become Health Innovation East. As of 1 October 2023, the government and NHS England announced their intention to relicense the 15 Academic Health Science Networks (AHSNs) in England as Health Innovation Networks.
Kathryn Chapman, BRCL, interviewed live on Sky News representing the Life Science Industry
28 November 2023
It was great to see Kathryn being interviewed live on the Business Programme of Sky News with Ian King, representing the Life Science sector.
100 experts from Graphcore, Arm, Google and Stripe come together to support the next generation of Cambridge startups
20 November 2023
Founders at the University of Cambridge opens applications to its first pre-seed accelerator.
UK Life Sciences will provide a shot in the arm for the British economy, three sector specialists claim (including Campus CEO Derek Jones)
20 November 2023
Babraham Research Campus Ltd CEO Derek Jones, BioMed Realty’s Colleen O’Connor, and JLL’s Chris Walters join Montfort’s Andrew Teacher to discuss the outlook for life sciences, the challenges of creating high-spec lab space, and why the success of the industry should be cause for optimism in the UK.
ViaNautis Bio announces $25 million Series A financing to drive the next generation of genetic nanomedicines
14 November 2023
ViaNautis Bio, a groundbreaking nanomedicine company at the forefront of genetic therapies, is excited to announce the successful completion of its Series A funding round, raising $25 million (£20 million).
BioMed Realty and Babraham Research Campus Announce Full Letting of Newest Life Science Development on Campus Ahead of Scheduled Completion
18 October 2023
BioMed Realty has completed the lease-up of a 34,000 square feet purpose-built, fully fitted wet laboratory building on the Babraham Research Campus ahead of scheduled completion.
Cambridgeshire and Cheshire take centre-stage at the Babraham Investor Conference 2023
22 September 2023
The Babraham Investor Conference 2023 (BIC) saw more than 150 company founders, investors and industry leaders come together at Babraham Research Campus yesterday, Thursday 21st September.
Ion Channel Drug Developer Maxion Therapeutics Appoints Eva-Lotta Allan as Chair of its Board of Directors
22 September 2023
Today, Maxion Therapeutics announced the appointment of senior industry leader Eva-Lotta Allan as the Chair of its Board of Directors.
Babraham Research Campus launches LiveLabs and announces Promega as inaugural sponsor
21 September 2023
Cementing its position as one of the best places to start-up and scale-up a life sciences venture in Europe, Babraham Research Campus today announced the launch of its new LiveLabs initiative.
BioBabraham Symposium highlights Campus’ ground-breaking research
13 September 2023
With the aim of encouraging collaborations within the Babraham Research Campus community, the inaugural BioBabraham Symposium, held earlier this summer, saw speakers from across the site present the remarkable scientific innovation taking place on Campus.
Babraham Research Campus and Equiem team up to elevate life science community experience
21 August 2023
Babraham Research Campus and Global proptech leader Equiem have announced a partnership that will provide an enhanced experience for the Campus’s life science community in Cambridge.
Accelerate@Babraham programme culminates in final pitching event
04 August 2023
The cohort of 2023 present findings and next steps to an invited audience at the Babraham Research Campus.
New schemes launched to further Campus collaboration
31 July 2023
The BioBabraham Symposium, which took place on Tuesday 18th July, saw the launch of three new initiatives for the Campus community to foster partnerships, including funding for new collaborations.
Crescendo takes cash haul to c.$150m after $32m raise and upscales cancer trial
25 July 2023
Crescendo Biologics, a clinical stage immuno-oncology company based in Cambridge, has taken its funding to date to almost $150 million with a fresh $32 million raise from global investors.
F-star, an invoX Company, Announces Strategic Collaboration and Licence Agreement with Takeda
13 July 2023
F-star Therapeutics today announced that it has entered into a strategic discovery collaboration and licence agreement with Takeda.
Babraham Research Campus announces new Board Appointment
12 June 2023
Babraham Research Campus Ltd (BRC), the organisation which oversees the development and day-to-day management of the Babraham Research Campus is delighted to welcome Charlie Foreman to the Board as non-executive director.
Cambridge Independent Science + Technology Awards.
22 May 2023
Congratulations to our Campus companies at the recent Cambridge Independent Science + Technology Awards.
Wildflower meadows
19 May 2023
Wondering why the grassland hasn't been mowed recently? It's all part of our ecology plan...read on.
Accelerate@Babraham 2023 Cohort Revealed
16 May 2023
Accelerate@Babraham, the Babraham Research Campus’ programme supporting early-stage life science ventures, announces new cohort.
Gogglebox Casting
16 May 2023
Studio Lambert Casting has reached out to Babraham Research Campus in search for some new cast members for their long running television show Gogglebox.
Maxion Therapeutics awarded £2 million Innovate UK funding to develop ion channel antibodies for “hard-to-treat" autoimmune diseases
20 April 2023
Biotechnology company Maxion Therapeutics announces it has been awarded a prestigious GBP £2 million grant from Innovate UK, as part of its Biomedical Catalyst 2022 Round 2: Industry-led R&D funding competition.
IUCT-Oncopole & Artios join forces to overcome resistance to therapies for familial breast cancer
20 April 2023
The IUCT-Oncopole is launching an ambitious national project in collaboration with Artios Pharma Limited.
Kadans Science Partner welcomes CHARM Therapeutics to B900 at the Babraham Research Campus, Cambridge
12 April 2023
The facility will act as the new R&D site for CHARM Therapeutics, providing the Company with the necessary capacity to support its growth plans as it continues to develop its transformational oncology pipeline.
F-star Therapeutics cashes in on new Takeda deal
11 April 2023
F-star in Cambridge – an invoX company – has entered into a second licence agreement with Takeda, the Japanese multinational pharma business, for a novel next-generation immuno-oncology bispecific antibody.
Cambridge Wide Open Day
06 April 2023
Explore the world-class science and technology facilities of Cambridge in one shot...
F-star Therapeutics acquired by invoX Pharma for $161m
17 March 2023
F-star Therapeutics has been acquired by invoX Pharma Limited for $161million.
Important roadworks information: A11 Babraham to Six Mile Bottom
08 March 2023
I am writing to tell you that we plan to carry out essential maintenance on the A11 between Babraham and Six Mile Bottom. This will involve safety barrier replacement, resurfacing and renewal of signs. This will ensure the A11 continues to remain in a safe and serviceable condition.
The Glenn Berge building has an official naming ceremony
03 March 2023
So who was Lt. Berge and why would we put his name on a building? Read on to find out.
Five Alarm Bio, Focused on Minimising the Effects of Aging in Humans, Raises Seed Investment
27 February 2023
Five Alarm Bio (FAB), a drug discovery company focused on novel approaches to anti-aging, announced today it has completed a seed investment round, raising over £500K GBP to further enable its pioneering research.
BBSRC ICURe is now live
21 February 2023
The next round of the BBSRC ICURe is now live! Applications close on Monday 27th March.
ROSPA CoSHH at Babraham Research Campus
20 February 2023
Places are available to attend a one- day ROSPA CoSHH course to be held at The Babraham Research Campus
Maxion Therapeutics’ $16 million Series A to drive antibody development for previously untreatable ion channel and GPCR-driven diseases
15 February 2023
Biotechnology company Maxion Therapeutics (‘Maxion’) today announced the completion of its USD $16 million (GBP £13 million) Series A financing.
Join bit.bio and help enable the medicines of the future
13 February 2023
At bit.bio, we are passionate about engineering human cells that will enable the medicines of the future.
Adrestia leads fight for new drugs to combat lethal children’s disease
13 February 2023
Adrestia Therapeutics has co-founded a research consortium to find new treatments for a potentially fatal disease.
Stemnovate and Babraham Institute come together to untangle the tauopathy in Alzheimer’s disease
02 February 2023
An exciting research collaboration ‘sprint’ is getting ready to launch on the Babraham Research Campus to better understand the role of an essential cellular process in brain health.
Linton Greenway Active Travel Path
20 January 2023
Work will be starting soon to connect the active travel path at Hildersham East, from the junction with the Hildersham High Street, to link up to the existing Linton Greenway at Dalehead Foods along the A1307. The works will commence in early February for approximately 16 weeks.
Enter the Start Up Awards!
20 January 2023
The StartUp Awards recognises the achievements of those amazing individuals who have had a great idea, spotted the opportunity and taken the risks to launch a new product or service.
CambridgeshireLive Business Awards
20 January 2023
Do you want to see your business' hard work recognised? Has your success sky-rocketed this year? Enter before the deadline on January 27
Kathryn Chapman meets with Campus companies to hear your views
13 January 2023
As part of Kathryn's focus to on identifying and delivering support for companies on Campus across all stages of growth, we met with Campus CEOs to get your views.
BioMed Realty Becomes New Strategic Partner to Babraham Research Campus Accelerate@Babraham Bio-incubator Programme
10 January 2023
The Babraham Research Campus is delighted to confirm BioMed Realty’s support for its Accelerate@Babraham bio-incubator programme.
Kathryn Chapman relishing challenge to grow Babraham Research Campus
06 January 2023
Dr Kathryn Chapman is relishing the challenges she has taken on as she steps into the new role of director, science and entrepreneurship at Babraham Research Campus.
Congratulations to Alchemab Therapeutics
05 January 2023
Alchemab Therapeutics awarded £1.7m from Innovate UK to develop Huntington’s disease therapy towards human trials
Qkine closes on an over subscribed funding round
29 December 2022
The fundraising will see Qkine, an A@B alumni, move to a new HQ
IMPORTANT CHANGES TO CLINICAL WASTE
23 December 2022
BRCL has undergone a review of its current clinical waste streams and wishes to make some improvements, read on to find out more.
o2h technology offering - applications required by end of Dec.
20 December 2022
o2h technology specializes in developing MVPs, custom products and special project builds covering web, mobile and cloud. Due to a cancellation of some work, the O2 tech team have space to do a project at cost/not for profit for a start-up that needs their support.
Making Connections 2022 Consultation
09 December 2022
Everyone living in Greater Cambridge can have their say on the Making Connections proposals - read on to see the new interactive bus map, to see how your journey to work could be impacted by more frequent bus services.
RxCelerate acquires Methuselah Health and launches ProQuant™ world-beating proteomics service
23 November 2022
RxCelerate, a leading international out-sourced drug discovery and development platform, today announced the acquisition of drug discovery company Methuselah Health UK Ltd for an undisclosed sum.
Babraham Research Campus Ltd appoints Kathryn Chapman as Director of Science & Entrepreneurship
21 November 2022
Babraham Research Campus Ltd is delighted to announce the appointment of Dr Kathryn Chapman to the newly created role of Director, Science & Entrepreneurship.
My STEMM Future is recruiting for guest speakers
18 November 2022
My STEMM Future is a collaboration between Wellcome Connecting Science, scientists at the Wellcome Genome Campus and The Youth STEMM Award.
The BBSRC ICURe EXPLORE Programme
11 November 2022
Up to £25k of funding and training is available for researchers, PhD students and technicians. Find out more.
Applications for PULSE 2023 are now open
09 November 2022
Aimed at aspiring entrepreneurs and first-time CEO's looking for advanced practical advice, support and feedback.
Campus Christmas Closure dates
07 November 2022
Find out when the Campus closes for Christmas and what services will be available.
Adrestia appoints Head of Chemistry and initiates multi-target partnership with Proteros to discover first-in-class drugs for intractable genetic diseases
03 November 2022
Adrestia Therapeutics announced the appointment of Dr James Osborne as Head of Chemistry and the initiation of a multi-target partnership with Proteros biostructures GmbH (Munich, Germany).
Duo join ethics and sustainability board as bit.bio adds two new cell products to ‘menu’
02 November 2022
Two new members have been welcomed to bit.bio’s independent ethics and sustainability board to further support the company’s commitment to being a purpose-led, ethical organisation.
Babraham Research Campus receives funding for barrier-busting PhD programme
31 October 2022
Babraham Research Campus Ltd and the Babraham Institute have secured funding for fifteen PhD studentships from UKRI-BBSRC as part of a Collaborative Training Partnership (CTP).
Signatures restaurant will reopen on 24 Oct
21 October 2022
Located in the Bennet building, Signatures Cafe will reopen as a self-service facility.
Do you love singing on your own or with others?
19 October 2022
Babraham Research Campus along with Cambridge Biomedical Campus and Granta Park are coming together to form a group of like-minded people who enjoy a good singalong.
Royal Mail Strikes
19 October 2022
Please be aware of the forthcoming Royal Mail Strikes. Click here for dates.
Babraham Institute mentoring scheme
12 October 2022
BI are looking for mentors from campus companies to mentor researchers and PhD students.
Lonza's Road to First in Human Webinar Series
10 October 2022
Lonza is sharing a series of five educational, free webinars entitled “ Expert Series: Road to First in Human” designed to help early-stage biotechs de-risk development projects, accelerate approval, maximise molecule values and simplify development.
BioMed Realty partners with Babraham Research Campus Limited to expand the Campus and its ecosystem
03 October 2022
BioMed Realty is expanding its footprint at the Babraham Research Campus following the formation of a joint venture with Babraham Research Campus to deliver a 40,000 square foot purpose-built building with new fitted laboratory space.
Campus Closure: Mon 19th Sept
15 September 2022
As a mark of respect, Babraham Research Campus Limited will be closed on Monday 19th September, the day of the Queen’s funeral.
WASTE AUDITOR VISIT 8th Sept
07 September 2022
Matt Antrobus our Head of Estates, will be walking around the Campus with a Waste Auditor tomorrow. They will be visiting buildings and tenanted areas, selected at random, and potentially looking to ask some questions of tenants about what clinical/hazardous wastes are being produced and how waste is segregated.
Springer Nature Exclusive Discount
05 September 2022
Babraham Research Campus tenants* can now claim 10% discount off ANY of Nature’s 90+ other journals.
Notice of Build Works on Campus
01 August 2022
Further to Planning Permission granted at the end of last year, we are now able to commence work on B960; the new building located directly South of B940 and B950.
Deck chairs for you to enjoy
28 July 2022
Feel free to enjoy the new deck chairs, located on the back lawn and beside Minerva
Call for funding proposals to the Babraham Research Campus Collaboration Fund
20 July 2022
In 2022/23, this UKRI-BBSRC fund awarded to Babraham Research Campus Ltd, will support five collaborative research projects each worth up to £30,000.
Logs, kindling and charcoal for sale
20 July 2022
The Estates team have seasoned firewood available for sale, produced from timber sourced on-site, which arises from tree surgery works around the campus, as well as from our Woodland Conservation Programme.
Investor conference returns in new hybrid format
30 June 2022
We were delighted to welcome over 70 investors back to the Campus for the Investor Conference, which was also streamed online to over 50 viewers.
Bicycle Therapeutics in-conversation with JLL
30 June 2022
Hear how the demand profile of life science companies changes as their businesses mature, and how real estate decisions are now primarily based on the desires and needs of employees in the post-pandemic world.
Female leaders join bit.bio with COO ‘proud of team we’re building’
24 June 2022
Kathryn Corzo took up the role of chief operating officer (COO) at synthetic biology company bit.bio in November.
Transine Therapeutics poised for growth with new CSO hire and tripling of lab space
23 June 2022
Transine Therapeutics today announced the appointment of Andy Billinton as Chief Scientific Officer as it triples its facility footprint at The Babraham Research Campus.
Dr Simon Cook appointed Institute Director
09 June 2022
The Board of Trustees is delighted to announce that Dr Simon Cook has been appointed as the Institute’s Director.
Five Cambridge companies in inaugural Growth Index study
01 June 2022
Five Cambridge companies have made it to the inaugural Growth Index, a ranking of the fastest growing companies in the UK based on a rigorous financial analysis of the compound annual growth of 32,000 companies.
Babraham Institute launches a new digital look
23 May 2022
There’s a fresh new look to the Babraham Institute’s website, click here to see the lighter, brighter and improved digital experience.
NVIDIA brings Alchemab into the Cambridge-1 supercomputer project
19 May 2022
Cambridge biotech pioneer Alchemab Therapeutics has been chosen by US tech giant NVIDIA to harness the power of the UK’s most powerful supercomputer, Cambridge-1.
15% off Cambs Cuisine
17 May 2022
Discount at CambsCuisine for all Babraham Research Campus staff
Benefits of plants in the office
17 May 2022
Why are plants so good for us in our workspace? The Good Plant Company can tell us why, including how you can work with them to improve your office.
Ongoing works to improve the River
17 May 2022
Major work has just been completed the river to improve habitat for wildlife, provide a better view of the river for walkers and improve the ability of the river to cope with floods and droughts.
Cambridge Independent Science & Technology Awards
12 May 2022
Delighted to see so many companies and Accelerate at Babraham alumni being recognised at the recent awards ceremony.
Sphere Fluidics strengthens commercial team with three new senior hires
12 May 2022
Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has appointed three new hires to its commercial team.
Cambridge company’s disease model sheds new light on Huntington’s
11 May 2022
A new disease model – one of the first of its kind to be made commercially available – is being hailed as a key pathfinder in reflecting the genetics of Huntington’s disease.
Abzena shows sixth sense with California expansion
05 May 2022
Life science power player Abzena, whose global headquarters is at Babraham Research Campus in Cambridge, has added a sixth site to its global operations network with expansion in California.
BBSRC Business and Academia Prosperity Partnership
05 May 2022
The BBSRC have released an £11m grant fund to support established research partnerships between business and academic institutions.
Assessing Life Sciences Skill Requirements in the Oxford Cambridge Arc
03 May 2022
Whitecap Consulting has been appointed by The Open University to research and analyse workforce skills and associated requirements in the growing Life Sciences sector in the Oxford-Cambridge Arc to 2030.
Nature Subscription: 45% discount for the world famous journal
28 April 2022
Exclusive discount offer for Babraham Research Campus tenants to the world-famous scientific journal Nature.
Supporting Cambridge's Life Sciences Ecosystem: Q&A With James Seppala and Tim Schoen
28 April 2022
James Seppala and Tim Schoen discuss BioMed Realty’s footprint in the UK and the opportunity in the life sciences real estate market in the years ahead.
Cambridge irons out the wrinkles in anti-ageing science arena
25 April 2022
Cambridge is playing a lead role in developing technology designed to rejuvenate skin cells and arrest the march of age-related diseases.
How Adrestia Therapeutics is pioneering synthetic rescue - an interview with Prof Steve Jackson and CEO Robert Johnson
19 April 2022
A new approach to tackling genetic diseases could unlock treatments to some of the most intractable conditions, it is hoped.
Old skins cells reprogrammed to regain youthful function. Findings could lead to targeted approach for treating ageing
08 April 2022
Research from the Babraham Institute has developed a method to ‘time jump’ human skin cells by 30 years, turning back the ageing clock for cells without losing their specialised function.
From ‘a metaphorical slap around the face’ to ‘life-saving’ - how life science start-ups view Accelerate@Babraham
04 April 2022
The latest cohort of five life science start-ups to complete the 2021/22 cycle of Accelerate at Babraham may have had the added pressure of a pandemic throughout the five-month programme but all made great strides to develop their business propositions, which in turn promises to change patient outcomes.
Alchemab selected to access NVIDIA Cambridge-1 supercomputer to advance machine learning enabled antibody discovery
24 March 2022
Alchemab Therapeutics has been selected by NVIDIA to harness the power of the UK’s most powerful supercomputer, Cambridge-1.
Volunteers help plant community forest garden with edible plants at Babraham Research Campus
03 March 2022
A community forest garden full of edible plants is being created within the estate of Babraham Research Campus, thanks to council funding and the work of volunteers.
Accelerate@Babraham alumni, Shift Bioscience is hiring!
21 February 2022
The longevity biotech company using machine learning to develop therapeutics for safe cellular reprogramming has three open positions.
‘Globally important’ Babraham Research Campus given go ahead to expand
25 January 2022
The Babraham Research Campus – one of the UK’s leading locations supporting early-stage bioscience enterprise – has been given the go ahead to expand, to ensure the UK life science research and development sector can continue to deliver world-changing health solutions.
We must rethink PhDs to smash barriers and ensure bioscience success
21 January 2022
Redesigning PhD training will help develop commercially savvy researchers, address skills gaps in UK bioscience and bolster innovation, say Simon Cook and Derek Jones.
There is still time to enter the CambridgeshireLive Business Excellence Awards 2022
19 January 2022
Entries for the awards close on Friday 21 January!
Sphere Fluidics closes $40m investment round to fund international expansion of Cyto-Mine technology
04 November 2021
Sphere Fluidics has closed a $40million (around £30m) investment round to expand its international sales activities.
Enterprising Minds: Man on a Mission
29 October 2021
An interview with Steve Jackson, Founder and former CSO of Mission Therapeutics; Founder, CSO and Interim CEO of Adrestia Therapeutics.
Bicycle Therapeutics wheels in $201.3m growth capital
25 October 2021
Transatlantic biotech game-changer Bicycle Therapeutics is wowing NASDAQ with its 12-month performance and fundraising magic.
TRx Biosciences launched with blessing of Yusuf Hamied and Babraham Research Campus
15 October 2021
Robin Bannister, TRx Biosciences’ CEO, said Cipla chairman Dr Yusuf Hamied is “a super investor to have on board” at the launch of TRx Biosciences on Babraham Research Campus yesterday.
Mission Therapeutics Awarded Follow-On Therapeutic Pipeline Program Grant from The Michael J. Fox Foundation
14 October 2021
Mission Therapeutics announced today that it has been awarded a Therapeutic Pipeline Program grant of approximately 0.5M USD from The Michael J. Fox Foundation for Parkinson’s Research (MJFF).
Lucy Cavendish College launches innovative and unique Life Sciences Community
24 September 2021
The supportive and inclusive collaboration will provide new opportunities for STEMM students and improve employment prospects.
CC Bio aims to improve health of millions of women and cystic fibrosis patients with microbiome editing technology
24 September 2021
The lives of millions of women around the world could be improved by extraordinary microbiome editing technology pioneered by synthetic biology start-up CC Bio.
Huntington’s disease progression stopped in cell study by University of Cambridge and UCL researchers
08 September 2021
Exciting progress has been made in the lab in the fight against Huntington’s disease. Scientists at the University of Cambridge and UCL have identified a mechanism that stops its progression in cells.
Cambridge Judge Business School are launching a new programme focusing on sustainability
26 August 2021
Would you like to be a part of the first ever Venture Creation: Sustainability cohort. Participation in the programme will help delegates develop their capacity for future innovation in addition to an entrepreneurial mindset that will support them throughout their career choices.
Ignite Founders’ Challenge - backing the next generation of early-stage entrepreneurs
26 August 2021
Judge Business School are delighted to announce Ignite Founder's Challenge starting in the Autumn term - is now open for applications. A specially designed four-week online programme for early-stage startups that consists of workshops and coaching sessions to transform your idea into a reality.
New technologies and early-stage ideas are needed for EnterpriseTECH student projects
26 August 2021
Judge Business School have an exciting opportunity for inventors. Would you like to find out if your early-stage research results or new or novel technology has commercial potential? Applications are open to submit project proposals for student teams to work on. The deadline for submissions is 6th September 2021.
Enabling Interaction
15 July 2021
Our CEO, Derek Jones speaks to UKSPA’s BreakThrough magazine about the history, evolution and achievements of the life sciences’ community at the Babraham Research Campus.
Over £200m invested in Babraham Campus companies in last year – but what lies ahead?
15 July 2021
The Babraham Investor Conference 2021 (BIC), an event for investors focusing on early-stage and scale-up life science and med-tech companies, moved online for the first time in its 15-year history.
Bicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis
14 July 2021
Bicycle Therapeutics today announced that Ionis Pharmaceuticals has exercised its option and entered into an exclusive worldwide license and collaboration agreement.
Adrestia Therapeutics in overdrive as it hires from new Cambridge HQ
14 July 2021
Cambridge life science business Adrestia Therapeutics is scaling fast as it accelerates its mission to rebalance disease and restore health.
New breast cancer drug could be ready within five years
14 July 2021
The treatment has been created by scientists at Cancer Research UK and Artios, a spin-out it set up in Cambridge to develop the drug which has received £90 million of funding.
The 25 Best Biotech Incubators Hatching Startup Stars in Europe
06 April 2021
Incubators can give biotech startups the boost they need to get off the ground. Accelerate@Babraham has made Labiotech's top 25 biotech incubators across Europe supporting the next generation of life science startups.